secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001558370-23-001631
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics CSO John Magnani to depart March 31; consulting through June 2024
-------------------------------------------------------------------------------

- Dr. John Magnani, SVP Research and CSO, employment ends March 31, 2023.
- Severance of $40,000 payable in equal installments over 3 months after separation.
- Company will pay COBRA premiums for 15 months post-separation.
- Consulting agreement from April 1, 2023 through June 30, 2024 for continued equity vesting.
- Consulting services provided at request of CEO or designee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837023001631/0001558370-23-001631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837023001631/glyc-20230221x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-001631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer